^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Colorectal Cancer
    Drug Class:Angiogenesis inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    BMC Cancer
    Title:

    Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

    Published date:
    01/14/2021
    Excerpt:
    This real-world, multicenter, retrospective, observational study included patients with BRAF V600-mutated mCRC treated in eight hospitals in Spain….Median OS was 11.8 months in patients who received antiangiogenic-based CT compared with 12.4 months in those who did not (hazard ratio [HR], 1.196; 95% CI, 0.7–2.1; p = 0.529) (Fig. 2b).
    DOI:
    10.1186/s12885-020-07758-5